Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials

BACKGROUND: Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IFNβ-1a IM). METHODS: This study compared...

Full description

Saved in:

Bibliographic Details
Published in:	Mult Scler Relat Disord
Main Authors:	Derfuss, Tobias, Ontaneda, Daniel, Nicholas, Jacqueline, Meng, Xiangyi, Hawker, Kathleen
Format:	Artigo
Language:	Inglês
Published:	2016
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4985567/ https://ncbi.nlm.nih.gov/pubmed/27456887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2016.05.015
Tags:	Add Tag No Tags, Be the first to tag this record!

Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials

Similar Items